A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid. (Q33497955)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8958188%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

title

A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8958188%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8958188%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

author name string

S Laohavinij

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8958188%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

S R Wedge

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8958188%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

M J Lind

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8958188%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

N Bailey

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8958188%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

A Humphreys

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8958188%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

M Proctor

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8958188%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

F Chapman

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8958188%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

D Simmons

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8958188%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

A Oakley

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8958188%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

L Robson

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8958188%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

L Gumbrell

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8958188%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

G A Taylor

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8958188%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

H D Thomas

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8958188%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

D R Newell

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8958188%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

A H Calvert

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8958188%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

publication date

1 January 1996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8958188%20AND%20SRC:MED&resulttype=core&format=json

Investigational New Drugs

21 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8958188%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8958188%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8958188%20AND%20SRC:MED&resulttype=core&format=json

21 October 2019

page(s)

325-335

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8958188%20AND%20SRC:MED&resulttype=core&format=json

Hypoxanthine as a Measurement of Hypoxia

21 October 2019

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF00194536

Growth-inhibitory effects of 5,10-dideazatetrahydrofolic acid on variant murine L1210 and human CCRF-CEM leukemia cells with different membrane-transport characteristics for (anti)folate compounds

21 January 2018

1 reference

12 December 2020

Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10- dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement

1 reference

12 December 2020

Prostaglandins: Modulators of Renal Function and Pressor Resistance in Chronic Liver Disease*

1 reference

12 December 2020

Whole-body autoradiographic disposition and plasma pharmacokinetics of 5,10-dideazatetrahydrofolic acid in mice fed folic acid-deficient or regular diets

1 reference

12 December 2020

Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis

1 reference

12 December 2020

HPLC analysis of aromatic amino acids, nucleosides, and bases in plasma of acute lymphocytic leukemia on chemotherapy

1 reference

12 December 2020

7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate

1 reference

12 December 2020

Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid

1 reference

12 December 2020

Intracellular metabolism of 5-formyl tetrahydrofolate in human breast and colon cell lines

1 reference

12 December 2020

Hypoxanthine concentrations in normal subjects and patients with solid tumors and leukemia

1 reference

12 December 2020

Impact of dietary folic acid on reduced folates in mouse plasma and tissues. Relationship to dideazatetrahydrofolate sensitivity

1 reference

12 December 2020

1 reference

12 December 2020

Acute renal failure and death following sequential intermediate-dose methotrexate and 5-FU: a possible adverse effect due to concomitant indomethacin administration

1 reference

12 December 2020

Methotrexate nephrotoxicity

1 reference

12 December 2020

Disposition of leucovorin and its metabolites in the plasma, intestinal epithelium, and intraperitoneal L1210 cells of methotrexate-pretreated mice

1 reference

12 December 2020

A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis

1 reference

12 December 2020

Synthesis of the antileukemic agents 5,10-dideazaaminopterin and 5,10-dideaza-5,6,7,8-tetrahydroaminopterin

1 reference

12 December 2020

The 6S- and 6R-diastereomers of 5, 10-dideaza-5, 6, 7, 8-tetrahydrofolate are equiactive inhibitors of de novo purine synthesis

1 reference

12 December 2020

Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate Toxicity

1 reference

12 December 2020

The clinical pharmacokinetics of the novel antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717)

1 reference

12 December 2020

Renal syndromes associated with nonsteroidal antiinflammatory drugs

1 reference

12 December 2020

Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen

1 reference

12 December 2020